SynthesisPloS one2024
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Multiplex PCR-Based Detection of Eight Carbapenemase Genes and Their Clinical Characteristics in Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility forMicrobiology spectrum · 2026Article
- In silico design of a multiepitope vaccine against antibiotic drug-resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Plumbagin Disrupts Biofilm Integrity and Resistance Gene Expression in Carbapenem-ResistantJournal of microbiology and biotechnology · 2026Article
- Whole-genome analysis of extensively drug-resistantMicrobiology spectrum · 2026Article
- Genetic diversity and antimicrobial resistance of clinical Acinetobacter baumannii isolates: insights from ERIC typing.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Clinical characteristics and risk factor analysis of multidrug-resistant bacterial bloodstream infections in adult acute leukemia patients.Frontiers in microbiology · 2026Article
- Prioritization of antimicrobial resistance surveillance of gram-negative pathogens - a stacked modelling approach.Wellcome open research · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Clinical characteristics and treatment outcomes ofMicrobiology spectrum · 2025Article
- Clinical Implications of Bacteremia Caused by Non-Biomedicines · 2025Article
- Relationship between antibiotic resistance and biofilm-forming capacity with RND efflux pumps expression in clinical Acinetobacter baumannii isolates.Archives of microbiology · 2025Article
- Clonality and the Phenotype-Genotype Correlation of Antimicrobial Resistance inMicroorganisms · 2025Article
- Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PloS one · 2025Article
- Correction: Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2025Article
- The intricacies ofFrontiers in microbiology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations.
methodsWe systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE. Quality assessment was performed using the JBI checklist. Subgroup analyses were performed based on the COVID-19 timeframes, years, countries, continents, and bias levels, antimicrobial susceptivity test method and guidelines.
resultsOur comprehensive meta-analysis, which included 795 studies across 80 countries from 1995 to 2023, revealed a surge in carbapenem resistance among A. baumannii, imipenem (76.1%), meropenem (73.5%), doripenem (73.0%), ertapenem (83.7%), and carbapenems (74.3%). Temporally, 2020-2023 witnessed significant peaks, particularly in carbapenems (81.0%) and meropenem (80.7%), as confirmed by meta-regression, indicating a steady upward trend.
conclusionThis meta-analysis revealed an alarmingly high resistance rate to CRAB as a global challenge, emphasizing the urgent need for tailored interventions. Transparency, standardized methodologies, and collaboration are crucial for the accurate assessment and maintenance of carbapenem efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.